

# Peter D Gorycki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/653925/publications.pdf>

Version: 2024-02-01

16  
papers

585  
citations

840776

11  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. <i>Chemico-Biological Interactions</i> , 1999, 121, 117-123.	4.0	137
2	Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 3111-3116.	2.2	132
3	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. <i>Xenobiotica</i> , 2013, 43, 443-453.	1.1	69
4	Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2215-2224.	3.3	41
5	Discovery of potent and orally bioavailable N,N <sup>2</sup> -diarylurea antagonists for the CXCR2 chemokine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4375-4378.	2.2	40
6	Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1734-1746.	3.3	40
7	Comparison of N,N <sup>2</sup> -diarylsquaramides and N,N <sup>2</sup> -diarylureas as antagonists of the CXCR2 chemokine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1713-1717.	2.2	37
8	Inhibition of topoisomerases by fredericamycin A. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 167-171.	2.3	28
9	Investigations of Hydrazine Cleavage of Eltrombopag in Humans. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1747-1754.	3.3	13
10	Structure-activity relationships for the inhibition of DNA polymerase $\beta$ by aphidicolin derivatives. <i>Nucleic Acids Research</i> , 1989, 17, 6339-6348.	14.5	12
11	Phosphorus-32-postlabeling analysis of DNA adduction in mouse skin following topical administration of (+)-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene. <i>Chemical Research in Toxicology</i> , 1992, 5, 26-33.	3.3	11
12	Metabolism of [ <sup>14</sup> C]GSK977779 in Rats and Its Implication with the Observed Covalent Binding. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1620-1632.	3.3	10
13	Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1314-1325.	3.3	8
14	The Oxidation of Tetrasubstituted Alkenes by Cytochrome P450. <i>Chemical Research in Toxicology</i> , 1994, 7, 745-751.	3.3	4
15	First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 234-245.	1.6	2
16	First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 334-345.	1.6	1